<?xml version='1.0' encoding='utf-8'?>
<document id="27751854"><sentence text="Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A."><entity charOffset="109-120" id="DDI-PubMed.27751854.s1.e0" text="Huperzine A" /></sentence><sentence text="Huperzine A (HupA), one of the reversible and selective acetylcholinesterase inhibitors derived from Chinese herb Huperzia Serrata, possesses affirmative action of ameliorating cognitive dysfunction of Alzheimer's disease"><entity charOffset="0-11" id="DDI-PubMed.27751854.s2.e0" text="Huperzine A" /><entity charOffset="13-17" id="DDI-PubMed.27751854.s2.e1" text="HupA" /><pair ddi="false" e1="DDI-PubMed.27751854.s2.e0" e2="DDI-PubMed.27751854.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27751854.s2.e0" e2="DDI-PubMed.27751854.s2.e1" /></sentence><sentence text=" Up to now, the effects of HupA on human cytochrome P450s (CYPs) have not been fully elucidated"><entity charOffset="27-30" id="DDI-PubMed.27751854.s3.e0" text="HupA" /></sentence><sentence text=" The purpose of the present study was to clarify the metabolic pathway of HupA in vitro and in vivo, and to evaluate the CYPs inhibition/induction profile of HupA in vitro"><entity charOffset="74-77" id="DDI-PubMed.27751854.s4.e0" text="HupA" /><entity charOffset="158-161" id="DDI-PubMed.27751854.s4.e1" text="HupA" /><pair ddi="false" e1="DDI-PubMed.27751854.s4.e0" e2="DDI-PubMed.27751854.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27751854.s4.e0" e2="DDI-PubMed.27751854.s4.e1" /></sentence><sentence text=" The catalytic activity of CYP enzymes (CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1 and 3A4) was measured by the quantification of specific enzyme substrates using validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) methods" /><sentence text=" The in vivo metabolic pathway evaluation was performed in an open, single-dose pharmacokinetic study of HupA in fourteen elderly subjects, with urine collecting at certain intervals"><entity charOffset="105-108" id="DDI-PubMed.27751854.s6.e0" text="HupA" /></sentence><sentence text=" In human liver microsomes, HupA (10 ng/mL) was not metabolized within 90 min, and it showed negligible inhibition against these CYP isoforms within 0"><entity charOffset="28-31" id="DDI-PubMed.27751854.s7.e0" text="HupA" /></sentence><sentence text="2-100 ng/mL" /><sentence text=" In human liver hepatocytes, the activities of CYP1A2 and CYP3A4 were not significantly altered when incubated at 2 or 20 ng/mL of HupA"><entity charOffset="131-134" id="DDI-PubMed.27751854.s9.e0" text="HupA" /></sentence><sentence text=" After oral administration of 0" /><sentence text="1 mg HupA, the total proportion of HupA excreted through urine was relatively high, accounting to 35± 9% at the limited time period of 48 h"><entity charOffset="5-8" id="DDI-PubMed.27751854.s11.e0" text="HupA" /><entity charOffset="35-38" id="DDI-PubMed.27751854.s11.e1" text="HupA" /><pair ddi="false" e1="DDI-PubMed.27751854.s11.e0" e2="DDI-PubMed.27751854.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27751854.s11.e0" e2="DDI-PubMed.27751854.s11.e1" /></sentence><sentence text=" These results suggest that HupA is substantially excreted by kidney unchanged rather than metabolized by human liver, and is unlikely to cause clinically relevant drug-drug interaction (DDI) when co-administrated with drugs that are metabolized by CYP isoenzyme system"><entity charOffset="28-31" id="DDI-PubMed.27751854.s12.e0" text="HupA" /></sentence><sentence text="" /></document>